EUVIMEDEUVIMED entdecken
Crossref

Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

José Angel García-Sáenz, Frederik Marmé, Michael Untch, Hervé Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole Mc Carthy, Karen Gelmon, Miguel Martin, Catherine M Kelly, Toralf Reimer, Masakazu Toi und 9 weitere

European Journal of Cancer · 2024-01 · 196 · 113420

DOI: 10.1016/j.ejca.2023.113420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024-01. Verfasst von José Angel García-Sáenz und 20 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain, and Spanish Breast Cancer Group, GEICAM, Madrid, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The PENELOPEB trial investigating efficacy and safety of additional 1-year post-neoadjuvant palbociclib to standard endocrine therapy (ET) high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer patients failed to improve invasive disease-free survival (iDFS). This analysis compared patient-reported outcomes (PROs) between treatment groups. PATIENTS AND METHODS: Patients received 13 cycles of palbociclib 125 mg/day (n = 631) or placebo (n = 619) orally for 3 out of 4 weeks + ET. European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30), its breast cancer (BR23) and fatigue (FA13) modules, mood questionnaire GAD7 and European Quality of Life 5 Dimensions (EQ-5D) instruments were used for the assessment of quality of life (QoL). Repeated-measures mixed-effects models were used to evaluate differences in PRO, changes of PRO over time, and treatment-by-time interactions. RESULTS: 924 of 1250 patients (73.9%) completed baseline and at least one post-baseline questionnaire of all PRO instruments. General health status (GHS)/QoL based on EORTC QLQ-C30 was high in both arms (mean [SD]: palbociclib 70.1 [19.3], placebo 71.4 [18.8]) and was slightly higher in the placebo arm (LeastSquare mean difference: 0.82, p < 0.001). Higher fatigue was reported in the palbociclib arm (mean [SD]: 30.3 [23.8] vs. placebo 28.3 [22.7]; p < 0.001). No statistically significant differences were observed among FA13 physical, cognitive, and emotional fatigue subscales. CONCLUSION: Patient-reported global QoL and fatigue did not substantially change in both treatment arms. Slight differences in GHS, physical functioning, and fatigue favored the placebo arm statistically without achieving clinically meaningful thresholds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleQuality of LifePatient Reported Outcome MeasuresFatigueAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesPiperazinesPyridines

Stichwörter der Autor:innen

Breast cancerHigh-risk HR+ /HER2- early breast cancerPalbociclibPost-neoadjuvantQoL

Substanzen

Erb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesPyridines

Autor:innen und Institutionen

  • Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain, and Spanish Breast Cancer Group, GEICAM, Madrid, Spain.
  • Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Germany.
  • Helios Kliniken Berlin-Buch, Germany.
  • Institut Bergonié and Université de Bordeaux INSERM U916, Bordeaux, France.
  • Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
  • Division of Surgical Oncology, Massey Cancer Center, Virginia Commonwealth University, VCU Health, Richmond, VA, USA.

Förderung

  • Pfizer Inc

Zitieren

APA

García-Sáenz, J. A., Marmé, F., Untch, M., Bonnefoi, H., Kim, S. B., Bear, H., Mc Carthy, N., Gelmon, K., Martin, M., Kelly, C. M., Reimer, T., Toi, M., Law, E., Bhattacharyya, H., Gnant, M., Makris, A., Seiler, S., Burchardi, N., Nekljudova, V., …, & Rugo, H. S. (2024). Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study. European Journal of Cancer, 196, 113420. https://doi.org/10.1016/j.ejca.2023.113420

Vancouver

García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, et al. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study. European Journal of Cancer. 2024;196:113420. doi:10.1016/j.ejca.2023.113420

BibTeX
@article{GarcaSenz2024,
  author = {García-Sáenz, José Angel and Marmé, Frederik and Untch, Michael and Bonnefoi, Hervé and Kim, Sung-Bae and Bear, Harry and Mc Carthy, Nicole and Gelmon, Karen and Martin, Miguel and Kelly, Catherine M and Reimer, Toralf and Toi, Masakazu and Law, Ernest and Bhattacharyya, Helen and Gnant, Michael and Makris, Andreas and Seiler, Sabine and Burchardi, Nicole and Nekljudova, Valentina and Loibl, Sibylle and Rugo, Hope S},
  title = {Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {196},
  pages = {113420},
  doi = {10.1016/j.ejca.2023.113420}
}
Kostenlos starten →